🇺🇸 Higher doses of vasopressor therapy for a MAP of 75 mmHg in United States

Higher doses of vasopressor therapy for a MAP of 75 mmHg (Higher doses of vasopressor therapy for a MAP of 75 mmHg) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Higher doses of vasopressor therapy for a MAP of 75 mmHg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Higher doses of vasopressor therapy for a MAP of 75 mmHg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Higher doses of vasopressor therapy for a MAP of 75 mmHg in United States?

Centre de recherche du Centre hospitalier universitaire de Sherbrooke is the originator. The local marketing authorisation holder may differ — check the official source linked above.